Browse

S-Space

Browsing by Subject NSCLC

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 24 of 24

Issue Date Title / Author(s) / CitationFile
2005
Predictive and prognostic impact of epidermal growth factor receptor (EGFR) mutation in non-small-cell lung cancer (NSCLC) patients treated with gefitinib (ZD1839)
link
2005
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
link
2005
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer
DOI
2008
Prognostic factors of non-small cell lung cancer with bone metastasis
link
2012
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis
DOI
2015
Ring-truncated deguelin analogue induces apoptosis and anti-angiogenesis in non-small cell lung carcinoma cells
view file
2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
DOI
2015
Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells
view fileDOI
2016
A Novel Synthetic Derivative of Deguelin, SH-174, Exhibits Anti-cancer Activities Against Non-small-cell Lung Cancer Cells
view file
2016
Biological Screening of Natural Compounds for Developing Anticancer Agents in Non-Small Cell Lung Cancer
view file
2016
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
view fileDOI
2016
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
DOI
2016
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer
DOI
2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
DOI
2017
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer
DOI
2017
Scientific Advances in Thoracic Oncology 2016
DOI
2017
ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)
DOI
2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
DOI
2018
Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer
DOI
2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
DOI
2019
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
DOI
2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
DOI
2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
DOI
2020
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
DOI
1
RSS 1.0 RSS 2.0 Atom

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr

Hello

Browse

News About S-Space Seoul National University Library LOGIN